How to Value a Vein Clinic in 2026

Vein clinics occupy an unusual position in healthcare M&A. They're medical practices, but they behave more like elective procedure businesses with a significant marketing component. The economics look nothing like a typical primary care or even a surgical specialty practice. Understanding those economics is the key to getting the valuation right.

I've seen vein clinic transactions range from single-physician offices doing $1M in revenue to multi-location platforms doing $15M+. The multiples vary significantly based on a handful of factors that are specific to this sub-specialty, and I'll walk through each of them.

The Valuation Range

Vein clinics typically trade at 4-8x EBITDA, which is a wider range than most medical specialties. The spread is driven almost entirely by the business model: a clinic running predominantly insurance-based medical procedures (endovenous laser ablation for symptomatic varicose veins) gets valued differently than one running predominantly cash-pay cosmetic procedures (sclerotherapy for spider veins).

Single-physician clinics at the lower end of revenue typically trade at 4-5x EBITDA or 1.5-2.5x SDE when selling to another physician. Multi-location platforms with employed physicians, strong brands, and proven marketing engines attract PE interest and trade at 6-8x EBITDA, with platform premiums for groups that can serve as consolidation anchors.

Procedure Volume: The Core Metric

Vein clinics are procedure-driven businesses, and buyers evaluate them primarily on procedure volume, mix, and reimbursement. The key procedures to understand:

• Endovenous laser ablation (EVLA): The bread-and-butter medical procedure. Insurance-reimbursed for symptomatic varicose veins. Reimbursement is typically $1,500-$3,000 per leg depending on payer and geography. High-volume clinics perform 15-30 ablations per week per physician.
• Radiofrequency ablation (RFA/ClosureFast):Similar to EVLA with comparable reimbursement. Some physicians prefer one over the other. Buyers don't differentiate between the two from a valuation standpoint.
• Sclerotherapy: Injection treatment for spider veins and small varicose veins. Often cosmetic (not covered by insurance), priced at $300-$500 per session. Lower revenue per procedure but higher margin and no insurance hassle.
• VenaSeal/ClariVein: Newer closure technologies. Insurance coverage is inconsistent, but when covered, reimbursement is similar to EVLA. The presence of newer technology signals a practice that stays current.
• Ambulatory phlebectomy: Surgical removal of surface veins, often performed alongside ablation. Insurance-covered. Adds $800-$1,500 per case.

A clinic performing 20 ablations per week, 15 sclerotherapy sessions, and 5 phlebectomies is generating roughly $60K-$90K in weekly procedure revenue from a single physician. The volume and consistency of that procedure throughput is what buyers underwrite.

Insurance vs. Cosmetic Revenue: The Mix Matters

This is where vein clinic valuation gets nuanced. Insurance-based medical procedures (ablations, phlebectomy) provide a stable revenue base but come with all the headaches of medical billing: prior authorizations, claim denials, reimbursement cuts, and slow payment cycles. Cosmetic procedures (most sclerotherapy, some laser treatments) are cash-pay with immediate collection and no billing overhead.

The optimal mix from a valuation standpoint is 60-70% insurance / 30-40% cosmetic. This gives you the revenue stability of insurance reimbursement combined with the margin enhancement of cash-pay cosmetic work. Clinics that are 90%+ insurance-dependent face reimbursement risk — Medicare and commercial payers have been tightening criteria for vein procedures, and a single policy change can materially impact revenue.

Clinics that are 80%+ cosmetic face a different risk: they're essentially elective aesthetic businesses that depend on consumer discretionary spending and marketing effectiveness. In a recession, cosmetic vein procedures are among the first things consumers cut.

Marketing-Driven Patient Acquisition

Unlike most medical specialties where referrals from primary care physicians drive patient volume, vein clinics are significantly marketing-driven. Most patients self-refer after seeing a TV commercial, Google ad, or social media post. This is both a strength and a vulnerability.

The strength is that patient acquisition is a controllable lever. A well-run vein clinic spends 8-15% of revenue on marketing and generates a predictable flow of new patient consultations. If you need more patients, you increase the marketing spend. This scalability is attractive to PE buyers building multi-location platforms.

The vulnerability is that marketing spend is essentially rent you pay for patient volume. Stop spending and new patients dry up within 30-60 days. Buyers will stress-test your marketing efficiency by examining your cost per consultation (typically $150-$400), consultation-to-procedure conversion rate (good clinics convert 60-75%), and lifetime patient value (the average patient generates $3,000-$8,000 in total procedure revenue).

A clinic with a proven, data-driven marketing machine — tracked cost per lead, per consultation, per procedure, across channels — is worth meaningfully more than one where the owner "thinks the TV ads are working" but can't prove it.

What Drives Premium Vein Clinic Valuations

Multiple physicians. A vein clinic with 2-3 employed physicians performing procedures is worth far more per dollar of EBITDA than a solo practitioner clinic. The buyer knows the business can survive one physician leaving, and the overhead is leveraged across multiple providers.

Multiple locations. Vein clinics scale well geographically because the procedures are office-based (no hospital affiliation needed), the equipment is portable, and a single physician can rotate between locations. A three-location clinic with a central marketing operation and shared back office looks like a platform to a PE buyer.

Ultrasound capabilities in-house. Diagnostic ultrasound is required before most vein procedures for insurance authorization. Clinics that perform their own diagnostic ultrasound capture that revenue ($200-$500 per study) rather than sending patients to a separate imaging center. It also streamlines the patient journey, improving conversion.

Strong prior authorization processes. Insurance companies increasingly require detailed documentation and prior authorization for vein procedures. Clinics with dedicated staff and high approval rates (above 85%) demonstrate operational sophistication that buyers value.

What Kills Vein Clinic Value

Payer concentration. If 50%+ of your procedure revenue comes from a single insurance company, one contract renegotiation or policy change can gut your profitability. Diversified payer mix is essential. Read about how concentration risk destroys value across industries.

Compliance issues. Vein clinics face intense scrutiny from payers and regulators around medical necessity documentation. If your clinic has a history of claim denials, audits, or recoupment demands, that's a serious red flag that will either kill the deal or result in substantial indemnification provisions.

Solo physician dependency. The owner-physician who performs every procedure, manages every patient relationship, and runs the marketing is the ultimate owner-dependent business. If you are the clinic, your EBITDA multiple drops 1-2 turns versus a practice with multiple providers.

Declining procedure volume. Year-over-year decline in total procedures performed, even if revenue is flat due to price increases, signals a market or operational problem that buyers will price in heavily.

The Bottom Line

Vein clinics that command 6-8x EBITDA are multi-provider operations with diversified revenue across insurance and cosmetic procedures, proven marketing engines with trackable ROI, clean compliance records, and multiple locations or clear expansion pathways. Single-physician clinics at 4-5x are still solid businesses, but the path to premium valuation requires building an organization that operates independently of the founding physician. In a consolidating market where PE-backed platforms like United Vein Centers and Vein Clinics of America continue to acquire, well-prepared multi-location vein practices are among the most sought-after assets in healthcare M&A.